Designing a new Vaccine Based on Multiple Epitopes Against Monkeypox Virus with the help of new Methods Based on Immunoinformatics Software Designing a new Vaccine Based on Multiple Epitopes Against Monkeypox Virus by Immunoinformatics Software
Iranian Journal of Pharmaceutical Sciences,
Vol. 18 No. 2 (2022),
1 Farvardin 2022
,
Page 160-175
https://doi.org/10.22037/ijps.v18.42143
Abstract
Monkeypox virus is a zoonotic virus belonging to the family of Poxviridae and the genus Orthopoxvirus, which is the cause of a viral disease between humans and animals, the characteristics of which are comparable to other cases of smallpox with some differences. Recently some patients caused by the monkeypox virus (MPXV) were reported to the WHO. In recent years, the widespread and rapid spread of some epidemics highlighted the need for the rapid development of effective vaccines in scientific communities. Although conventional therapies have played an essential role in the treatment of many diseases, emerging diseases require new methods of treatment with fewer complications. It is therefore important to develop an effective vaccine for infections caused by the Monkeypox virus to prevent mortality and the safety of the community. In this research, we have used bioinformatics to design a vaccine against the F13 envelope protein Monkeypox virus. A total epitope confined to B cells and MHC I and II alleles were structurally constructed in F13 envelope protein to stimulate immunity and antibody recognition which was used to construct a chimeric peptide vaccine. The vaccine was predicted as a stable, antigenic, and non-allergenic combination. analysis of the TRL4/vaccine docking complex and simulation indicate a sufficiently stable binding with receptor activation. The immune response simulation following hypothetical immunization indicates the potential for stimulation and production of active and memory B cells, as well as the potential for cell production of CD8 + T, CD4 + T, and the development of effective immunological responses induced by Th2 and Th1. Analysis of the in silico processes have shown that the structure of the vaccine produces high antigenicity and good cellular immunity in the host body and stimulates various immune receptors such as TLR4, MHC I and MHC II. Vaccine function was also associated with increased IgM and IgG and a set of Th1 and Th2 cytokines. But final confirmation of the effectiveness of the designed vaccine requires clinical processes.
- Vaccines, Monkeypox virus, Immunology, Bioinformatics, Envelope protein, Docking.
How to Cite
References
[2] Cimerman S, Chebabo A, Cunha CAD, Barbosa AN and Rodríguez-Morales AJ. Human monkeypox preparedness in Latin America - Are we ready for the next viral zoonotic disease outbreak after COVID-19? Braz J Infect Dis. (2022) 26 (3): 102372.
[3] Heymann DL, Szczeniowski M and Esteves K. Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull. (1998) 54 (3): 693-702.
[4] Bunge EM, Hoet B, Chen L, Lienert F, et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis. (2022) 16 (2): e0010141.
[5] Chastel C. [Human monkeypox]. Pathol Biol (Paris). (2009) 57 (2): 175-83.
[6] Jamil H, Tariq W, Tahir MJ, Mahfooz RS, Asghar MS and Ahmed A. Human monkeypox expansion from the endemic to non-endemic regions: Control measures. Ann Med Surg (Lond). (2022) 79: 104048.
[7] Mazurkov OY, Kabanov AS, Shishkina LN, Sergeev AA, et al. New effective chemically synthesized anti-smallpox compound NIOCH-14. J Gen Virol. (2016) 97 (5): 1229-39.
[8] Beer EM and Rao VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Negl Trop Dis. (2019) 13 (10): e0007791.
[9] Nalca A, Rimoin AW, Bavari S and Whitehouse CA. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis. (2005) 41 (12): 1765-71.
[10] Kugelman JR, Johnston SC, Mulembakani PM, Kisalu N, et al. Genomic variability of monkeypox virus among humans, Democratic Republic of the Congo. Emerg Infect Dis. (2014) 20 (2): 232-9.
[11] Esposito JJ and Knight JC. Orthopoxvirus DNA: a comparison of restriction profiles and maps. Virology. (1985) 143 (1): 230-51.
[12] Hammarlund E, Lewis MW, Carter SV, Amanna I, et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med. (2005) 11 (9): 1005-11.
[13] Notice to Readers: Supplemental Recommendations on Adverse Events Following Smallpox Vaccine in the Pre-Event Vaccination Program: Recommendations of the Advisory Committee on Immunization Practices. MMWR Morbidity and mortality weekly report 2003; 52(13):282-4. (2003) 52 (13).
[14] Rotz LD, Dotson DA, Damon IK and Becher JA. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep. (2001) 50 (Rr-10): 1-25; quiz CE1-7.
[15] Lo YT, Pai TW, Wu WK and Chang HT. Prediction of conformational epitopes with the use of a knowledge-based energy function and geometrically related neighboring residue characteristics. BMC Bioinformatics. (2013) 14 Suppl 4 (Suppl 4): S3.
[16] Li W, Joshi MD, Singhania S, Ramsey KH and Murthy AK. Peptide Vaccine: Progress and Challenges. Vaccines (Basel). (2014) 2 (3): 515-36.
[17] Peters B, Sidney J, Bourne P, Bui HH, et al. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol. (2005) 3 (3): e91.
[18] Khalil I, Omer I, Farh IZA, Mohamed HA, et al. Design of an epitope-based peptide vaccine against Cryptococcus neoformans. bioRxiv. (2018): 434779.
[19] Sormanni P, Aprile FA and Vendruscolo M. The CamSol method of rational design of protein mutants with enhanced solubility. J Mol Biol. (2015) 427 (2): 478-90.
[20] Maupetit J, Derreumaux P and Tuffery P. PEP-FOLD: an online resource for de novo peptide structure prediction. Nucleic Acids Res. (2009) 37 (Web Server issue): W498-503.
[21] Robinson J, Guethlein LA, Cereb N, Yang SY, et al. Distinguishing functional polymorphism from random variation in the sequences of >10,000 HLA-A, -B and -C alleles. PLoS Genet. (2017) 13 (6): e1006862.
[22] Kozakov D, Hall DR, Xia B, Porter KA, et al. The ClusPro web server for protein-protein docking. Nat Protoc. (2017) 12 (2): 255-78.
[23] Dimitrov I, Naneva L, Doytchinova I and Bangov I. AllergenFP: allergenicity prediction by descriptor fingerprints. Bioinformatics. (2014) 30 (6): 846-51.
[24] Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R and Raghava GP. In silico approach for predicting toxicity of peptides and proteins. PLoS One. (2013) 8 (9): e73957.
[25] Ikai A. Thermostability and aliphatic index of globular proteins. J Biochem. (1980) 88 (6): 1895-8.
[26] Ali M, Pandey RK, Khatoon N, Narula A, Mishra A and Prajapati VK. Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. Sci Rep. (2017) 7 (1): 9232.
[27] Thévenet P, Shen Y, Maupetit J, Guyon F, Derreumaux P and Tufféry P. PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res. (2012) 40 (W1): W288-W93.
[28] Shen Y, Maupetit J, Derreumaux P and Tufféry P. Improved PEP-FOLD Approach for Peptide and Miniprotein Structure Prediction. J Chem Theory Comput. (2014) 10 (10): 4745-58.
[29] Liu W, Chen M, Li X, Zhao B, et al. Interaction of Toll-Like Receptors with the Molecular Chaperone Gp96 Is Essential for Its Activation of Cytotoxic T Lymphocyte Response. PLoS One. (2016) 11 (5): e0155202.
[30] Ansari HR and Raghava GP. Identification of conformational B-cell Epitopes in an antigen from its primary sequence. Immunome Res. (2010) 6: 6.
[31] Mauldin MR, McCollum AM, Nakazawa YJ, Mandra A, et al. Exportation of Monkeypox Virus From the African Continent. J Infect Dis. (2022) 225 (8): 1367-76.
[32] Sun P, Ju H, Liu Z, Ning Q, et al. Bioinformatics resources and tools for conformational B-cell epitope prediction. Comput Math Methods Med. (2013) 2013: 943636.
[33] Sant'Angelo DB, Robinson E, Janeway CA, Jr. and Denzin LK. Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor. Eur J Immunol. (2002) 32 (9): 2510-20.
[34] Koretzky GA. Multiple roles of CD4 and CD8 in T cell activation. J Immunol. (2010) 185 (5): 2643-4.
[35] Khalil I, Omer I, Farh IZA, Mohamed HA, et al. Design of an epitope-based peptide vaccine against Cryptococcus neoformans. bioRxiv. (2018): 434779.
[36] Sanchez-Trincado JL, Gomez-Perosanz M and Reche PA. Fundamentals and Methods for T- and B-Cell Epitope Prediction. J Immunol Res. (2017) 2017: 2680160.
[37] Naz, Anam, et al. "Identification of putative vaccine candidates against Helicobacter pylori exploiting exoproteome and secretome: a reverse vaccinology-based approach. Infect. Genet. Evol. 32 (2015): 280-291.
[38] Liu W, Chen M, Li X, Zhao B, et al. Interaction of Toll-Like Receptors with the Molecular Chaperone Gp96 Is Essential for Its Activation of Cytotoxic T Lymphocyte Response. PLoS One. (2016) 11 (5): e0155202.
[39] Chukwudozie OS, Chukwuanukwu RC, Iroanya OO, Eze DM, et al. Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In Silico Analysis. J Immunol Res. (2020) 2020: 2837670.
[40] Bhattacharyya A, Boostanpour K, Bouzidi M, Magee L, et al. IL10 trains macrophage profibrotic function after lung injury. Am J Physiol Lung Cell Mol Physiol. (2022) 322 (3): L495-l502.
- Abstract Viewed: 92 times
- IJPS-Vol18- Issue 2-page 160-175 Downloaded: 37 times